50 results about "Antibiotic sensitivity" patented technology

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

The invention relates to the technical field of bacterial drug sensitivity detection, and discloses a method for rapidly detecting bacterial antibiotic sensitivity, which comprises the following steps: (1) preparing a mixed solution from a bacterial strain liquid to be detected, antibiotics and glucose, and incubating to obtain a mixed reagent; (2) adding a viable bacterium coloring agent and a dead bacterium coloring agent with different fluorescence colors into the mixed reagent for dyeing; and (3) respectively detecting the fluorescence intensity corresponding to the viable bacterium coloring agent and the dead bacterium coloring agent, and judging the antibiotic sensitivity of the bacteria according to the fluorescence intensity. By adopting the method disclosed by the invention, the reaction of the to-be-detected strain to the antibiotics can be accelerated, and the time required for detecting the antibiotic sensitivity of the bacteria is shortened.

The invention discloses a high-throughput bacterial drug sensitivity test platform based on computer vision. The platform integrates the functions of automatic separation and identification of bacteria, drug sensitivity test and result analysis. Separation and identification of bacteria are realized through a microfluidic technology, and growth conditions of the bacteria under the action of different antibiotics are monitored in real time in combination with a computer vision technology, so that the antibiotic sensitivity of the bacteria is rapidly judged. The platform has the characteristics of high throughput, automation and intellectualization, can complete detection of a large number of samples in a short time, automatically generates a drug sensitivity test report, and provides powerful support for clinical diagnosis and treatment. By implementing the method, the speed and the accuracy of the bacterial drug sensitivity test are remarkably improved, and the method has a wide application prospect.

The embodiment of the invention discloses a primer group and application. Specific primers are designed for a UreA gene, a GyrA gene, a 23SrRNA gene, a PbP1 gene, a 16SrRNA gene, a porD gene, a CagA gene, a vacA gene, a CYP2C19 * 2 gene, a CYP2C19 * 3 gene, a CYP2C19 * 17 gene and mutation sites on the basis of a nucleic acid mass spectrometry technology, the helicobacter pylori detection kit has the advantages of high sensitivity and high accuracy, and helicobacter pylori identification, antibiotic sensitivity / drug resistance detection and virulence gene typing can be quickly and efficiently carried out; the method for detecting the metabolic type of the proton pump inhibitor has a good application prospect.

The invention relates to a plant lactobacillus JN-7, bacterial powder, a preparation method, a probiotic composition and application thereof. According to the application, a new plant lactobacillus strain is obtained through screening, the new plant lactobacillus strain is named as plant lactobacillus JN-7, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.30605. Basic characteristic analysis (growth curve, acid resistance, cholate resistance and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolysis capability, toxin production capability and cytotoxicity), adhesiveness evaluation, anti-inflammatory action evaluation, production performance evaluation (fermentation yield and freeze-drying yield) and stability test (accelerated storage stability test) of the strain are carried out; it is found that the plant lactobacillus JN-7 is a safe strain and has excellent production performance, high stability and an anti-inflammatory effect. The bacterial powder produced by the bacterial strain can keep stable and active for a long time.

The invention discloses a preparation method and application of athlete-derived bifidobacterium probiotics for intestinal barrier repair, and relates to the technical field of biochemistry and microorganisms, and the preparation method comprises the steps of special bacteria source sampling, directional separation and purification, molecular biological identification, antibiotic sensitivity evaluation and injury repair verification. According to the preparation method and application of the sportsman-derived bifidobacterium probiotics for repairing the intestinal barrier, the sportsman intestinal flora is used as an exclusive bacterial source, and the unique metabolic elite attribute and stress adaptability of the sportsman intestinal flora are utilized to directionally screen and obtain a bifidobacterium strain adaptive to an extreme physiological stress environment; the bottleneck that conventional probiotics are only suitable for a common physiological environment and the survival rate and activity in a stress state are greatly reduced is broken through, high survival rate and metabolic activity can be kept in extreme environments such as exercise heat stress and the like, and accurate repair of intestinal barriers is realized through multiple mechanisms; meanwhile, an exclusive screening, identification and safety evaluation system is established, so that the safety and functional specificity of the strain are ensured.

A plant lactobacillus JN9, a preparation, a probiotic composition and its use. The present application obtains a new plant lactobacillus JN9 through screening, and the deposit number is: CCTCC NO: M 20241647. Through the basic characteristic analysis (growth curve, acid resistance, bile salt resistance, gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic ability, toxin production ability, cytotoxicity, ability to produce bioamines), adhesion evaluation, GABA production evaluation, alcohol tolerance and acetaldehyde dehydrogenase production ability evaluation of the strain, it is found that it is a safe strain with excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase enzyme activity. It can be used to improve mood such as relieving stress, anti-depression and improving the body's sleep quality, lowering blood pressure, anti-diabetes, anti-cancer, anti-oxidation, anti-inflammatory, anti-microbial, anti-allergic, and enhancing alcohol tolerance during drinking and relieving discomfort after drinking.

The invention discloses an application of Limosilicilla fermentum WMSN-2 in the aspect of preventing neonatal necrotizing enterocolitis, and belongs to the field of application of probiotics. The invention further discloses a preparation method of the Limosilicilla fermentum WMSN-2 for preventing neonatal necrotizing enterocolitis. The lactobacillus mucus WMSN-2 strain provided by the invention has bacteriostatic ability, antibiotic sensitivity and good gastrointestinal fluid tolerance, has the effect of preventing and treating neonatal necrotizing enterocolitis, can reduce the disease activity index of neonatal necrotizing enterocolitis individuals, and can be used for treating neonatal necrotizing enterocolitis. The survival rate is improved; the small intestine shortening and intestinal villus injury are relieved. The lactobacillus mucus WMSN-2 strain provided by the invention can be used for preparing medicines for preventing and treating neonatal necrotizing enterocolitis, can also be used for preparing functional foods and feeds, and has a wide application prospect.

1. Name of the product of this design: An electronic device having an operation display portion with a cascaded graphical user interface for constructing an antibiotic sensitivity test for microorganisms. 2. Purpose of this design product: This design product is used for an electronic device. 3. The key design features of this design product lie in the content requiring protection of the graphical user interface. 4. The picture or photo that best illustrates the key points of the design: main view. 5. Purpose of the graphical user interface: Overall purpose of the interface: For microorganisms in patient samples, clinicians use the interface to determine the drugs to which the microorganisms are susceptible and build cascades for candidate drug families. If the microorganisms show resistance to drugs in the previous layer, users can create multiple layers to prevent over-selection of antibiotics to prevent the microorganisms from developing resistance. The part of the interface is the operation display part of the cascade graphical user interface. The buttons on the left side of the interface allow users to add new cascades or view existing cascades; the two buttons in the upper right corner of the interface are used to delete and save cascades; users can enter the cascade name in the first rectangular box from the left at the top, click the second rectangular box to select the biological interpretation group, and click the third rectangular box to select the style type; users can edit the drug family name by clicking the pen icon in the middle of the interface, click the "Select drug" rectangular box to select a specific drug, and click the "+" rectangular box on the right to add a new drug cascade; click the "+" rectangular box at the bottom to add a new drug family. After the user clicks the rectangular box "Select drug" in the middle of the main view to select a drug, the interface changes to Change State Figure 1; after the user clicks the rectangular box "Select drug" in Change State Figure 1 to select a drug, the interface changes to Change State Figure 2; after the user clicks the rectangular box with a "+" symbol on the middle right of the interface in Change State Figure 2, the interface changes to Change State Figure 3; after the user clicks the rectangular box "Select drug" in the second column in the middle of Change State Figure 3 to select a drug, the interface changes to Change State Figure 4; after the user clicks the rectangular box with a "+" symbol on the middle right of Change State Figure 4, the interface changes to Change State Figure 5; after the user clicks the rectangular box with a "+" symbol at the bottom of the interface in Change State Figure 5 to add a new drug family, the interface changes to Change State Figure 6; after the user clicks the rectangular box "Select drug" in the second group of drug families in Change State Figure 6 to select a drug, the interface changes to Change State Figure 7; after the user clicks the rectangular box with a "+" symbol at the bottom of Change State Figure 7 to add a new drug family, the interface changes to Change State Figure 8. 6. Other situations that require explanation: The contents in the dotted part of the figure are not subject to protection.

The present invention relates to a novel peptide derived from Hirudo nipponia, which has antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity. With antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity, the novel peptide derived from Hirudo nipponia according to the present invention can be advantageously applied as a material for various purposes in the pharmaceutical field, food field, cosmetic field, and agriculture and livestock industries. In addition, the novel antimicrobial peptide derived from Hirudo nipponia according to the present invention increases the sensitivity of antibiotics to multidrug-resistant bacteria, thereby markedly enhancing antimicrobial activity against multidrug-resistant bacteria when used in combination with antibiotics. Accordingly, a composition of the present invention comprising the peptide as an active ingredient can be advantageously used as a pharmaceutical composition for enhancing antibiotic sensitivity. In particular, the novel peptide of the present invention has very low hemolytic activity and cytotoxicity, and thus is safe for the human body. Moreover, the novel peptide of the present invention not only has excellent activity even under a high salt concentration, but also maintains activity even in a serum environment, thereby having high stability when applied in vivo.

The utility model relates to the technical field of drug sensitive paper sheet distributors, and particularly discloses a distributor facilitating use of drug sensitive paper sheets in a laboratory, which comprises a bottom support, a shell and a material pushing assembly, a supporting plate with inner and outer layers of circumferential discharging holes is arranged on the inner side of the bottom support, the shell is connected with the bottom support through a rotary limiting assembly, and the inner and outer layers of circumferential medicine tube grooves and the discharging holes are arranged in a staggered mode in the radial direction. The pushing assembly is composed of a stand column, a base, a pressing rod, a push rod, a tension spring and an ejector pin, the pressing rod drives the push rod to laterally move through a first inclined guide face, and the ejector pin completes the ejection action of the medicine sensitive paper on the lowermost layer of the medicine tube under the reset action of the tension spring. The paper storage capacity is multiplied through the design of inner and outer double-layer medicine tube grooves, and the collaborative operation requirement of multiple types of paper sheets is met; shell rotation positioning is matched with trumpet-shaped discharging hole guiding, and it is guaranteed that the paper sheets accurately fall into circumferential equidistant positions of the culture dish.

A platform and method for testing antibiotic sensitivity of a polymicrobial infection is provided. The platform includes a body defining a plurality of sets of chambers and a plurality of wells. Each set of chambers has a plurality of chambers adapted for culturing microbes of the polymicrobial infection therein. Each well is associated with a corresponding set of chambers and has an input in fluidic communication with the outlets of the plurality of chambers in the corresponding set of chambers. Selected antibiotic therapies may be received in the wells which fluidically connect the plurality of chambers in a corresponding set of chambers such that microbes cultured in the plurality of chambers in the corresponding set of chambers are in soluble factor contact.

The present invention relates to a method, a device for carrying out the method and a kit for quickly determining antibiotic sensitivity and antibiotic resistance by directly measuring bacterial growth in bodily fluids. The present invention relates to the field of health, microbiology, diagnostics and prognosis, and of therapy guidance by evaluating the effectiveness of antibiotics and antibiotic combinations in human and veterinary medicine. The described embodiments relate to determining bacterial growth in samples of bodily fluids ex vivo in the presence of antibiotics added to the samples. The bacterial growth is determined in a device which enables the effectiveness of antibiotics to be immediately monitored in a kit after addition of an aliquot of a bodily fluid in that electric resistance, current flow, impedance or optical measurements are recorded using (fluorescent) dyes, the data are compared with reference values and the data are evaluated by way of programmed calculations and adapted mathematical methods.

The invention relates to a rapid antibiotic sensitivity detection and identification method, and the identification method can carry out antibiotic sensitivity detection and identification detection in a single process, and rapidly provide antibiotic information suitable for microorganisms. The invention provides a rapid antibiotic sensitivity detection and identification method which comprises the following steps: (a) transferring a sample extracted from a patient to a first reaction space in which a sample separation device exists; (b) capturing pathogens in a sample from a patient by a separation device within the first reaction space to separate and concentrate them; and (c) performing the identification of said pathogens or the detection of antibiotic sensitivity.

A complex microbial agent having an antibacterial effect, and a use thereof in preparation of yoghourt. The complex microbial agent comprises Lacticaseibacillus rhamnosus FMBL L23004CNN and Lactiplantibacillus plantarum FMBL L23036 CNN, wherein the Lacticaseibacillus rhamnosus FMBL L23004CNN is preserved in the China Center for Type Culture Collection on 26 June 2023, and the preservation number is CCTCC NO: M 20231099; and the Lactiplantibacillus plantarum FMBL L23036 CNN is preserved in the China Center for Type Culture Collection on 26 June 2023, and the preservation number is CCTCC NO: M 20231101. The complex microbial agent has the effect of preventing and / or treating diarrhea, and further has antibiotic sensitivity, and yoghourt obtained by means of fermentation by the complex microbial agent as a yoghurt starter has high activity.

The invention relates to the field of food, in particular to probiotic characteristics of lactobacillus salivarius JCF5 and a method for preparing Jersey yogurt through synergistic fermentation of the lactobacillus salivarius JCF5. The strain provided by the invention is named as Lactobacillus salivarius JCF5, and the Latin is Ligillactobacillussavarius. The invention further discloses a preparation method of the strain. The strain provided by the invention has the advantages that the strain is named as Lactobacillus salivarius JCF5; the strain is obtained by randomly selecting six newly-born Jersey and six Jersey-and-cattle hybrid calves with good health conditions from a pasture in Heilongjiang province, collecting fetal manure of the Jersey and six Jersey-and-cattle hybrid calves after the Jersey and cattle hybrid calves are born, and separating manure samples after the Jersey and cattle hybrid calves eat colostrum. The water-holding capacity and whey precipitation rate of the Jersey yoghourt can be remarkably improved, and the viscosity of the Jersey yoghourt can be increased. In addition, the strain has better acid resistance, cholate resistance and simulated gastrointestinal fluid resistance, does not show hemolysis capacity and gelatinase activity, has stronger antibacterial capacity and antibiotic sensitivity, and has the characteristics of probiotics. The application potential of the strain in fermenting the Jersey yogurt is fully explored, the quality of the Jersey yogurt is expected to be improved by changing the strain proportion of the leavening agent sold in the market, and a new leavening agent is provided for fermentation of the Jersey yogurt.

Lactiplantibacillus plantarum JN-7, a bacterial powder, a preparation method, a probiotic composition and the use thereof. According to the present application, a new strain of Lactiplantibacillus plantarum named Lactiplantibacillus plantarum JN-7 with the deposit number of CGMCC No. 30605 is obtained by means of screening. By means of basic characteristic analysis (growth curve, acid resistance, bile salt resistance, and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic capacity, toxigenic capacity, and cytotoxicity), adhesion evaluation, anti-inflammatory effect evaluation, production performance evaluation (fermentation yield and lyophilization yield), and stability tests (an accelerated storage stability test) of this strain, it is found that Lactiplantibacillus plantarum JN-7 is a safe strain with an excellent production performance, high stability, and an anti-inflammatory efficacy. The bacterial powder produced therefrom can remain stable and active for a long time.

The invention discloses an application of a breast milk-derived plant lactobacillus in improving allergic diseases and regulating intestinal flora, and belongs to the technical field of microorganisms. The plant lactobacillus GDMCC No: 63060 disclosed by the invention is obtained by being separated from breast milk. The strain provided by the invention has excellent gastrointestinal fluid tolerance, mucin adhesion and antibiotic sensitivity, can inhibit various pathogenic bacteria, can generate indole derivatives, effectively inhibits eczema mouse dermatitis symptoms, inhibits Th2 type immunoreaction hyperpolarization, and induces regulatory T cells. Therefore, the lactobacillus plantarum FN029 has a huge application prospect in preparation of products for inhibiting enteropathogenic bacteria, improving allergic diseases, regulating intestinal flora or promoting digestion function.

Disclosed in the present invention are a Lactiplantibacillus plantarum strain JN9, a preparation, a probiotic composition and the use thereof. The present application finds a novel Lactiplantibacillus plantarum strain JN9 by means of screening, and the accession number thereof is: CCTCCNO: M20241647c. By means of analysis of basic characteristics of the strain (growth curve, acid tolerance, bile salt tolerance and gastrointestinal fluid tolerance), safety evaluation (antibiotics sensitivity, hemolysis capacity, toxin production capacity, cytotoxicity and bioamine production capacity), adhesion evaluation, GABA production evaluation, alcohol tolerance evaluation and acetaldehyde dehydrogenase production capability evaluation, said strain is found to be a safe strain, and exhibits GABA production performance, alcohol tolerance and acetaldehyde dehydrogenase activity

The present disclosure introduces an AI-based empirical antibiotic recommendation system (100) designed to analyse patient data and recommend antibiotic treatments. The system (100) integrates with user devices via REST APIs and ensures secure operation through HTTPS. Client modules collect and pre-process raw data, ensuring integrity and compatibility. The pre-processed data is sent to the server (104) and forwarded to an input module (112) for authentication and validation. A processing module (114) standardizes the data, while a prediction module (116) identifies probable organisms and their antibiotic sensitivities. A clinical pathway module (118) generates dosing guidelines, and a prediction response module (120) displays the top three organisms with associated probabilities and recommended antibiotics. The antibiotics are color-coded for safety, and a feedback mechanism allows continuous system refinement.

The present invention relates to a kit for identifying bacteria and determining antibiotic sensitivity. The kit of the present invention includes the following components: a differential media formulation; distilled water; a color developer; a set of antibiotics; a control test; a set of Eppendorf tubes and a dropper. The differential media formulation includes peptone- 03gm by weight%, meat Extract-02gm by weight% and a nitrate source-0.6gm by weight%. the kit of the present invention enables bacterial identification and determining antibiotic susceptibility in lesser time than that of the conventional tests thereby reducing the time required in the treatment of urinary tract infection and thus reducing the incidences of antibiotic resistance.

Compositions and methods of preventing, slowing the progression of, or targeting antibiotic tolerance and increasing antibiotic sensitivity in intracellular bacteria. Compositions and methods of reducing the production of reactive oxygen and nitrogen species in a subject and methods of reducing antibiotic-tolerant persister cells. Methods can further include administration of antibiotics.

The present application relates to a Limosilactobacillus fermentum MSJK0025 from breast milk for adjusting gut microbiota and an application thereof. The Limosilactobacillus fermentum MSJK0025 from breast milk is preserved in China General Microbiological Culture Collection Center, with a preservation number of CGMCC No.26426. The Limosilactobacillus fermentum from breast milk provided in the present application is a new strain separated from the healthy nursing woman, named as "Limosilactobacillus fermentum MSJK0025", having good antibiotics sensitivity, and its property can be stably inherited. It has good resistance to acid, bile salt, and artificial gastric juice and intestinal juice, and fast growth rate and good safety. At the same time, the strain has strong survival capability in the gut, and effectively inhibits pathogenic bacteria in the gut such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, and Candida albicans, but does not inhibit the probiotic in the gut such as lactobacillus and bifidobacterium, so the strain has broad application prospect in adjusting the balance of gut microbiota.

The invention discloses a cotton bollworm source pediococcus acidilactici with gossypol degradation capability and application thereof, and belongs to the technical field of microorganisms, the cotton bollworm source pediococcus acidilactici with gossypol degradation capability is classified and named as JYM-1, the preservation unit is China Center for Type Culture Collection, the preservation number is CCTCCM2025009, and the preservation number is CCTCCM2025009. The 16SrDNA sequence of the cotton bollworm source pediococcus acidilactici is as shown in SEQ ID NO: 1. Probiotics capable of degrading gossypol are separated from intestinal tracts of cotton bollworms, the probiotic characteristics and safety of the probiotics are evaluated through tests of gossypol tolerance, gossypol detoxification capacity, antioxidant capacity, bacteriostatic activity, gastrointestinal stability, antibiotic sensitivity, non-hemolysis and the like, and the nutritional quality of the cottonseed meal can be remarkably improved by fermenting the cottonseed meal with the probiotics. The achievement of the invention provides a new method for improving the safety and nutritional value of the cottonseed meal as the feed, and is also beneficial to developing new probiotic resources and promoting the innovative development of the feed industry.

The present invention belongs to the technical field of biomedicine, and particularly relates to the application of linoleic acid in the preparation of a medicament for enhancing the antibiotic sensitivity of Gram-positive bacteria. The present invention discovers for the first time that the combination of linoleic acid and an antibiotic can significantly enhance the antibiotic sensitivity of Gram-positive bacteria; in vivo research data shows that the combination of linoleic acid and an antibiotic can not only improve the survival rate of mice infected with Gram-positive bacteria, but also enhance the ability of mice to eliminate Gram-positive bacteria; further, an anti-infective composition prepared from linoleic acid and an antibiotic can, on the one hand, achieve a significant clinical anti-infective effect, and on the other hand, prolong the post-antibiotic effect; moreover, linoleic acid is an essential fatty acid in human and animal nutrition, has high nutritional value, and has been widely used in foods and drugs, with high safety.

According to one aspect of the present invention, an electronic device for performing antibiotic sensitivity detection of a microorganism may comprise: a processor for: obtaining antibiotic data, the antibiotic data being data measured according to a change in an electrical characteristic of a target microorganism under antibiotic treatment; judging whether the antibiotic data is positive or negative, and inputting the positive control group data, the negative control group data and the antibiotic data of the target microorganism into a trained deep learning model, the deep learning model judges whether the antibiotic data is positive or negative according to the positive control group data, the negative control group data and the antibiotic data of the target microorganism; and identifying antibiotic sensitivity information of the target microorganisms according to different antibiotic types and concentrations by using the judgment result.

This invention provides methods, materials and systems for high throughput screening of Mtb for PDIM production. In some aspects, the invention provides culture media and kits that maintain, stimulate and / or augment PDIM production and / or prevents PDIM loss in mycobacterial culture in vitro, which in some aspects provides unexpectedly for clinically meaningful methods and materials for the rapid diagnosis of Mtb infection and antibiotic sensitivity of Mtb strains. In still other aspects, the invention provides methods / materials / kits and other means to exploit the link between propionate metabolism and PDIM production and applications of same for therapeutic efficacy, dosage efficacy in Mtb therapy, in addition to providing a high throughput means to assess Mtb drug resistance, for clinically meaningful applications.

The invention relates to a bactericidal adjuvant, which comprises a preparation capable of knocking out, knocking down or silencing a coding gene of alanine dehydrogenase of bacteria, or a preparation capable of destroying the alanine dehydrogenase function of the bacteria. By knocking out the ald gene, the sensitivity of aeromonas veronii to antibiotics is remarkably improved, and a brand-new technical method is provided for treatment of drug-resistant bacteria.

Lactiplantibacillus plantarum JN-7, a bacterial powder, a preparation method, a probiotic composition and the use thereof. According to the present application, a new strain of Lactiplantibacillus plantarum named Lactiplantibacillus plantarum JN-7 with the deposit number of CGMCC No. 30605 is obtained by means of screening. By means of basic characteristic analysis (growth curve, acid resistance, bile salt resistance, and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic capacity, toxigenic capacity, and cytotoxicity), adhesion evaluation, anti-inflammatory effect evaluation, production performance evaluation (fermentation yield and lyophilization yield), and stability tests (an accelerated storage stability test) of this strain, it is found that Lactiplantibacillus plantarum JN-7 is a safe strain with an excellent production performance, high stability, and an anti-inflammatory efficacy. The bacterial powder produced therefrom can remain stable and active for a long time.

The present disclosure relates to a microchamber device (1) for antibiotic sensitivity testing of bacterial cells (12) of a range of bacterial cell sizes, the microchamber device (1) being arranged on a substrate (40). The invention relates to a microchamber device (1) comprising a microchamber (11), a fluid inlet (14) and a fluid outlet (16) in fluid communication with the microchamber (11), and an integrated sensor (18) arranged in the microchamber (11), the sensor (18) being configured to monitor properties of bacterial cell activity in the microchamber (11) in real time and characterized in that the microchamber (11) comprises at least one trapping device (20), the trapping device (20) being configured to trap bacterial cells in the microchamber (11). And at least one sensor configured to capture at least one bacterial cell (12) in the microchamber (11). The present disclosure also relates to a test system (2) comprising at least one microchamber device (1) and a method for performing an antibiotic sensitivity test on bacterial cells (12).